Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein

Virology Journal

Volumn 2, Issue , 2005, Pages

  Bossart, Katharine N ^b   Mungall, Bruce A ^a   Crameri, Gary ^a   Wang, Lin Fa ^a   Eaton, Bryan T ^a   Broder, Christopher C ^b  

^a CSIRO   (Australia)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROGOL; PEPTIDE DERIVATIVE; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN; ANTIVIRUS AGENT; F PROTEIN, NIPAH VIRUS; GLYCOPROTEIN; PEPTIDE; VIRUS ENVELOPE PROTEIN;

ACETYLATION; AMIDATION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL FUSION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; HALF LIFE TIME; HENDRA VIRUS; HENIPAVIRUS; HENIPAVIRUS INFECTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MEMBRANE FUSION; NIPAH VIRUS; NONHUMAN; PEPTIDE SYNTHESIS; PROTEIN MODIFICATION; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS INHIBITION; ANIMAL; BIOLOGICAL MODEL; CERCOPITHECUS; DRUG ANTAGONISM; GENETICS; HELA CELL; PHYSIOLOGY; SYNTHESIS; VERO CELL; VIRUS ENTRY;

ANIMALIA; HENDRA VIRUS; HENIPAVIRUS; NIPAH VIRUS; PARAMYXOVIRIDAE;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; GLYCOPROTEINS; HELA CELLS; HENIPAVIRUS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, BIOLOGICAL; PEPTIDES; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 24944483017     PISSN: 1743422X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1743-422X-2-57     Document Type: Article

References (70)

1. Murray K, Selleck P, Hooper P, Hyatt A, Gould A, Gleeson L, Westbury H, Hiley L, Selvey L, Rodwell B, et al.: A morbillivirus that caused fatal disease in horses and humans. Science 1995, 268:94-97.
2. Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PS, Ksiazek TG, Zaki SR, Paul G, Lam SK, Tan CT: Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia [see comments]. Lancet 1999, 354:1257-1259.
3. Barclay AJ, Paton DJ: Hendra (equine morbillivirus). Vet J 2000, 160:169-176.
4. Wong KT, Shieh WJ, Kumar S, Norain K, Abdullah W, Guarner J, Goldsmith CS, Chua KB, Lam SK, Tan CT, Goh KJ, Chong HT, Jusoh R, Rollin PE, Ksiazek TG, Zaki SR: Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. Am J Pathol 2002, 161:2153-2167.
5. Wang LF, Yu M, Hansson E, Pritchard LI, Shiell B, Michalski WP, Eaton BT: The exceptionally large genome of Hendra virus: support for creation of a new genus within the family Paramyxoviridae. J Virol 2000, 74:9972-9979.
6. Wang L, Harcourt BH, Yu M, Tamin A, Rota PA, Bellini WJ, Eaton BT: Molecular biology of Hendra and Nipah viruses. Microbes Infect 2001, 3:279-287.
7. Field H, Young P, Yob JM, Mills J, Hall L, Mackenzie J: The natural history of Hendra and Nipah viruses. Microbes Infect 2001, 3:307-314.
8. Enserink M: Emerging infectious diseases. Nipah virus (or a cousin) strikes again. Science 2004, 303:1121.
9. Anonymous: Nipah virus outbreak(s) in Bangladesh, January-April 2004. Wkly Epidemiol Rec 2004, 79:168-171.
10. Butler D: Fatal fruit bat virus sparks epidemics in southern Asia. Nature 2004, 429:7.
11. Anonymous: Vol. 2 No. 2 June 2004 Person-to-person transmission of Nipah virus during outbreak in Faridpur District, 2004. Health and Science Bulletin (ICDDR,B) 2004, 2:5-9.
12. Hsu VP, Hossain MJ, Parashar UD, Ali MM, Ksiazek TG, Kuzmin I, Niezgoda M, Rupprecht C, Bresee J, Breiman RF: Nipah Virus Encephalitis Reemergence, Bangladesh. Emerg Infect Dis 2004, 10:2082-2087.
13. Bonaparte MI, Dimitrov AS, Bossart KN, Crameri G, Mungall BA, Bishop KA, Choudhry V, Dimitrov DS, Wang LF, Eaton BT, Broder CC: Ephrin-B2 Ligand is a Functional Receptor for Hendra Virus and Nipah Virus. Proc Natl Acad Sci U S A 2005, In Press:.
14. Baker KA, Dutch RE, Lamb RA, Jardetzky TS: Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell 1999, 3:309-319.
15. Lamb RA, Kolakofsky D: Paramyxoviridae: The viruses and their replication. In Fields Virology 4th edition. Edited by: Knipe DM and Howley PM. Philadelphia, Lippincott Williams & Wilkins; 2001:1305-1340.
16. Scheid A, Choppin PW: Two disulfide-linked polypeptide chains constitute the active F protein of paramyxoviruses. Virology 1977, 80:54-66.
17. Klenk HD, Garten W: Host cell proteases controlling virus pathogenicity. Trends Microbiol 1994, 2:39-43.
18. Earp LJ, Delos SE, Park HE, White JM: The many mechanisms of viral membrane fusion proteins. Curr Top Microbiol Immunol 2005, 285:25-66.
19. Weissenhorn W, Dessen A, Calder LJ, Harrison SC, Skehel JJ, Wiley DC: Structural basis for membrane fusion by enveloped viruses. Mol Membr Biol 1999, 16:3-9.
20. Chan DC, Kim PS: HIV entry and its inhibition. Cell 1998, 93:681-684.
21. Skehel JJ, Wiley DC: Coiled coils in both intracellular vesicle and viral membrane fusion. Cell 1998, 95:871-874.
22. Singh M, Berger B, Kim PS: LearnCoil-VMF: computational evidence for coiled-coil-like motifs in many viral membranefusion proteins. J Mol Biol 1999, 290:1031-1041.
23. Hughson FM: Enveloped viruses: a common mode of membrane fusion? Curr Biol 1997, 7:R565-9.
24. Xu Y, Gao S, Cole DK, Zhu J, Su N, Wang H, Gao GF, Rao Z: Basis for fusion inhibition by peptides: analysis of the heptad repeat regions of the fusion proteins from Nipah and Hendra viruses, newly emergent zoonotic paramyxoviruses. Biochem Biophys Res Commun 2004, 315:664-670.
25. Bossart KN, Wang LF, Eaton BT, Broder CC: Functional expression and membrane fusion tropism of the envelope glycoproteins of Hendra virus. Virology 2001, 290:121-135.
26. Chambers P, Pringle CR, Easton AJ: Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J Gen Virol 1990, 71:3075-3080.
27. Xu Y, Lou Z, Liu Y, Cole DK, Su N, Qin L, Li X, Bai Z, Rao Z, Gao GF: Crystallization and preliminary crystallographic analysis of the fusion core from two new zoonotic paramyxoviruses, Nipah virus and Hendra virus. Acta Crystallogr D Biol Crystallogr 2004, 60:1161-1164.
28. Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SRJ: Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A 1996, 93:2186-2191.
29. Joshi SB, Dutch RE, Lamb RA: A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41. Virology 1998, 248:20-34.
30. Wild TF, Buckland R: Inhibition of measles virus infection and fusion with peptides corresponding to the leucine zipper region of the fusion protein. J Gen Virol 1997, 78:107-111.
31. Young JK, Li D, Abramowitz MC, Morrison TG: Interaction of peptides with sequences from the Newcastle disease virus fusion protein heptad repeat regions. J Virol 1999, 73:5945-5956.
32. Young JK, Hicks RP, Wright GE, Morrison TG: Analysis of a peptide inhibitor of paramyxovirus (NDV) fusion using biological assays, NMR, and molecular modeling. Virology 1997, 238:291-304.
33. Rapaport D, Ovadia M, Shai Y: A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses. Embo J 1995, 14:5524-5531.
34. Bossart KN, Wang LF, Flora MN, Chua KB, Lam SK, Eaton BT, Broder CC: Membrane fusion tropism and heterotypic functional activities of the nipah virus and hendra virus envelope glycoproteins. J Virol 2002, 76:11186-11198.
35. Bossart KN, Broder CC: Viral glycoprotein-mediated cell fusion assays using vaccinia virus vectors. Methods Mol Biol 2004, 269:309-332.
36. Weiss CD: HIV-1 gp41: mediator of fusion and target for inhibition. AIDS Rev 2003, 5:214-221.
37. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998, 4:1302-1307.
38. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A: The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002, 18:685-693.
39. Rockstroh JK, Mauss S: Clinical perspective of fusion inhibitors for treatment of HIV. J Antimicrob Chemother 2004, 53:700-702.
40. Chen L, Gorman JJ, McKimm-Breschkin J, Lawrence LJ, Tulloch PA, Smith BJ, Colman PM, Lawrence MC: The structure of the fusion glycoprotein of Newcastle disease virus suggests a novel paradigm for the molecular mechanism of membrane fusion. Structure (Camb) 2001, 9:255-266.
41. Rost B, Liu J: The PredictProtein server. Nucleic Acids Res 2003, 31:3300-3304.
42. Hofmann K, Stoffel W: TMbase - A database of membrane spanning proteins segments. Biol Chem Hoppe-Seyler 1993, 374:166.
43. Gallaher WR, Ball JM, Garry RF, Griffin MC, Montelaro RC: A general model for the transmembrane proteins of HIV and other retroviruses [see comments]. AIDS Res Hum Retroviruses 1989, 5:431-440.
44. Gallaher WR, Ball JM, Garry RF, Martin-Amedee AM, Montelaro RC: A general model for the surface glycoproteins of HIV and other retroviruses. AIDS Res Hum Retroviruses 1995, 11:191-202.
45. Earl PL, Broder CC, Doms RW, Moss B: Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol 1997, 71:2674-2684.
46. Harcourt BH, Tamin A, Ksiazek TG, Rollin PE, Anderson LJ, Bellini WJ, Rota PA: Molecular characterization of Nipah virus, a newly emergent paramyxovirus. Virology 2000, 271:334-349.
47. Harris JM, Martin NE, Modi M: Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001, 40:539-551.
48. Francis GE, Fisher D, Delgado C, Malik F, Gardiner A, Neale D: PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. Int J Hematol 1998, 68:1-18.
49. Hyatt AD, Zaki SR, Goldsmith CS, Wise TG, Hengstberger SG: Ultrastructure of Hendra virus and Nipah virus within cultured cells and host animals. Microbes Infect 2001, 3:297-306.
50. Anonymous: Hendra Virus - Australia (Queensland). In Pro-med, International Society for Infectious Diseases; 2004.
51. Anonymous: Emerging Infections update: November 2004 to January 2005. Communicable Disease Report Weekly (CDR Weekly) 2005, 15:.
52. Chong HT, Kamarulzaman A, Tan CT, Goh KJ, Thayaparan T, Kunjapan SR, Chew NK, Chua KB, Lam SK: Treatment of acute Nipah encephalitis with ribavirin. Ann Neurol 2001, 49:810-813.
53. Dimitrov DS: Cell biology of virus entry. Cell 2000, 101:697-702.
54. Russell CJ, Jardetzky TS, Lamb RA: Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. Embo J 2001, 20:4024-4034.
55. Eckert DM, Kim PS: Mechanisms of Viral Membrane Fusion and Its Inhibition. Annu Rev Biochem 2001, 70:777-810.
56. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994, 91:9770-9774.
57. Jiang S, Lin K, Strick N, Neurath AR: HIV-1 inhibition by a peptide. Nature 1993, 365:113.
58. Young JK, Hicks RP, Wright GE, Morrison TG: The role of leucine residues in the structure and function of a leucine zipper peptide inhibitor of paramyxovirus (NDV) fusion. Virology 1998, 243:21-31.
59. Delgado C, Pedley RB, Herraez A, Boden R, Boden JA, Keep PA, Chester KA, Fisher D, Begent RH, Francis GE: Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. Br J Cancer 1996, 73:175-182.
60. Delgado C, Malik F, Selisko B, Fisher D, Francis GE: Quantitative analysis of polyethylene glycol (PEG) in PEG-modified proteins/cytokines by aqueous two-phase systems. J Biochem Biophys Methods 1994, 29:237-250.
61. Caliceti P, Veronese FM: Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003, 55:1261-1277.
62. Veronese FM: Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001, 22:405-417.
63. Harrington RD, Geballe AP: Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4-expressing human cell line. J Virol 1993, 67:5939-5947.
64. Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, Patch JR, Choudhary A, Wang LF, Eaton BT, Broder CC: Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble g glycoprotein of hendra virus. J Virol 2005, 79:6690-6702.
65. Fuerst TR, Niles EG, Studier FW, Moss B: Eukaryotic transientexpression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci USA 1986, 83:8122-8126.
66. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
67. Wang LF, Michalski WP, Yu M, Pritchard LI, Crameri G, Shiell B, Eaton BT: A novel P/V/C gene in a new member of the Paramyxoviridae family, which causes lethal infection in humans, horses, and other animals. J Virol 1998, 72:1482-1490.
68. Crameri G, Wang LF, Morrissy C, White J, Eaton BT: A rapid immune plaque assay for the detection of Hendra and Nipah viruses and anti-virus antibodies. J Virol Methods 2002, 99:41-51.
69. Nussbaum O, Broder CC, Berger EA: Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusiondependent reporter gene activation. J Virol 1994, 68:5411-5422.
70. Michalski WP, Crameri G, Wang L, Shiell BJ, Eaton B: The cleavage activation and sites of glycosylation in the fusion protein of Hendra virus. Virus Res 2000, 69:83-93.